Products
Nonacog gamma is commercially available as an injectable (Rixubis). It has been approved in many countries since 2014. In the United States, the drug went on sale in 2013.
Structure and properties
Nonacog gamma is a recombinant blood clotting factor IX produced by biotechnological methods. The amino acid sequence corresponds to that of the allelic form Ala148. Nonacog gamma is a glycoprotein and a vitamin K-dependent serine protease.
Effects
Nonacog gamma (ATC B02BD04) replaces the missing natural blood clotting factor IX and enables blood clotting. As a result, bleeding is prevented.
Indications
For the prevention and treatment of bleeding in patients with pretreated hemophilia B (congenital factor IX deficiency).
Dosage
According to the SmPC. The drug is administered as an intravenous injection.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include taste disturbance, pain in the extremities, and a positive test for furin antibodies.
